Search

Search results

717 results found

Pregnancy Outcomes After Exposure to Certolizumab Pegol: Updated Results From a Pharmacovigilance Safety Database.

Clowse, Megan E B, Angela E Scheuerle, Christina Chambers, Anita Afzali, Alexa B Kimball, John J Cush, Maureen Cooney, Laura Shaughnessy, Mark Vanderkelen, and Frauke Förger. 2018. “Pregnancy Outcomes After Exposure to Certolizumab Pegol: Updated Results From a Pharmacovigilance Safety Database.”. Arthritis & Rheumatology (Hoboken, N.J.) 70 (9): 1399-1407.

Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials.

Jemec, G B E, M M Okun, S B Forman, W P F Gulliver, E P Prens, U Mrowietz, A W Armstrong, et al. 2019. “Adalimumab Medium-Term Dosing Strategy in Moderate-to-Severe Hidradenitis Suppurativa: Integrated Results from the Phase III Randomized Placebo-Controlled PIONEER Trials.”. The British Journal of Dermatology 181 (5): 967-75.